FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 10/2024”.
The Monitor is a monthly published overview of venture capital trends in the European Healthcare & Life Sciences sector.
As of the end of October 2024 we identified the following current VC trends in Europe:
- Total Healthcare & Life Sciences funding reached EUR 31,125m
- Biotech/Pharma received 54% of the total investment volume (EUR 16,712m) with oncology being the leading indication (28%)
- In October Treeline Biosciences secured the highest transaction volume with EUR 381m, followed by Kailera Therapeutics with EUR 360m and Alpha-9 Oncology with EUR 159m
- RA Capital Management (United States) is the most active investor (by deal volume in 2024), followed by ARCH Venture Partners (United States) and Atlas Venture (United States)
To access the full report, please click here.